Latest Updates
-
Baisakhi 2026: Date, History, Rituals and Cultural Significance Explained -
At 83, Amitabh Bachchan Finds Not Working Each Day Disturbing: Why Breaking Routine Triggers Anxiety -
Alia Bhatt Serves Sharp, Subtle Drama in Gaurav Gupta’s Black Three-Piece Tuxedo -
Boss Lady By Zlaata: Workwear That Made Confidence Visible -
These 6 Seemingly Harmless Lifestyle Habits May Be Increasing Your Colorectal Cancer Risk -
World Health Day 2026: Grand Master Akshar Explains How Yoga Can Help Manage Diabetes and Hypertension -
Dal Khichdi Recipe: A Light Comfort Meal Everyone Loves -
From Hashtags to Merch Drops: How Fandom Fashion Became Part of the Story -
₹1000 Crore and Counting: ‘Dhurandhar 2’ Isn’t Just a Hit, It’s a Box Office Phenomenon -
Akshaya Tritiya 2026 Date: April 19 or 20? Know The Right Day To Buy Gold This Year
Alembic Pharma Gets Tentative USFDA Approval For Depressive Disorder Drug
Alembic Pharmaceuticals Ltd on Friday said it has received tentative approval from the US health regulator for its generic Vortioxetine tablets indicated for the treatment of the major depressive disorder.

The tentative approval granted by the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Vortioxetine tablets of strengths in 5 mg, 10 mg, 15 mg and 20 mg, the company said in a statement.
These are therapeutically equivalent to the reference listed drug product (RLD) Trintellix tablets 5 mg, 10 mg, 15 mg, and 20 mg of Takeda Pharmaceuticals, USA, Inc, it added. Citing IQVIA data, the company said.
These Vortioxetine tablets have an estimated market size of USD 1,249 million for twelve months ending September 2021. Citing IQVIA data, the company said these Vortioxetine tablets have an estimated market size of USD 1,249 million for twelve months ending September 2021.
Alembic, however, said it is currently in litigation with H Lundbeck in the Court of appeals for the Federal Circuit and the launch of the product will depend on litigation outcome.
"It is possible that our ANDA may not be indicated for certain uses due to unexpired exclusivities for the RLD for such uses," the company said.
Image Source: Freepik.com
Mental Health Helpline Numbers:
1. COOJ Mental Health Foundation (COOJ)- Helpline: 0832-2252525 | 01:00 PM - 07:00 PM (Monday to Friday)
2. Parivarthan- Helpline: +91 7676 602 602 | 10:00 AM to 10:00 PM (Monday to Friday)
3. Connecting Trust- Helpline: +91 992 200 1122 | +91-992 200 4305 | 12:00 PM to 08:00 PM (All days of the week)
4. Roshni Trust- Helpline: 040-66202000, 040-66202001 | 11:00 AM - 09:00 PM (Monday to Sunday)
5. Sahai Helpline: 080-25497777 / Email at - SAHAIHELPLINE@GMAIL.COM | 10 AM- 8 PM (Monday to Saturday)
6. Sumaitri: 011-23389090 / FEELINGSUICIDAL@SUMAITRI.NET |2 PM- 10 PM (Monday To Friday); 10 AM - 10 PM (Saturday and Sunday)
7. Sneha: 044-24640050 (24 HOURS) / 044-24640060 | Email at- HELP@SNEHAINDIA.ORG |8 AM - 10 PM
8. Lifeline: 033-24637401 / 033-24637432 | Email at LIFELINEKOLKATA@GMAIL.COM | 10 AM - 6 PM.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











